A person with neuroblastoma, which occurs when developing nerve cells in children turn cancerous, has remained tumour-free ...

A patient has achieved over 18 years of remission from neuroblastoma, a type of nerve cell cancer, following treatment with ...

The evolution of cell and gene therapy is reshaping drug discovery, providing new hope for rare diseases and cancer through innovative gene editing approaches.

An 18-year survivor of neuroblastoma, a solid childhood tumor that develops in immature nerve cells, is believed to represent ...

The FDA has accepted an investigational new drug application for ALLO-329, an allogeneic chimeric antigen receptor T-cell ...

A groundbreaking study in Nature Medicine reveals that GD2 CAR-T cell therapy can lead to long-term remission in children ...

Editor’s note: This is an automatically generated transcript. Please notify [email protected] if there are concerns regarding accuracy of the transcription.

Interviews revealed what patients and their caregivers focus on and needed support throughout the CAR-T therapy trajectory.

In 2018, England was the first country in Europe to provide access to a CAR-T cell therapy to treat these blood cancers, enabled via the Cancer Drugs Fund (CDF). Since then, over 500 patients in ...

Rezvani said there was a need for an off-the-shelf cancer cell therapy given the difficulties the US system is having with the newly approved CAR-T therapies. Companies are also trying to develop ...

TG Therapeutics will use MaxCyte’s technology to advance toward a clinical trial its azer-cel CAR T-cell therapy for ...

The off-the-shelf chimeric antigen receptor (CAR) T-cell therapy P-BCMA-ALLO1 was shown to be safe and elicited strong anti-tumor activity in patients with relapsed/refractory multiple myeloma, ...